Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

LIMN

Liminatus Pharma Inc

0.1078

Jul 27 • 9:31 AM ET -0.0031 (-2.80%)

Healthcare Biotechnology USA Nano NASD

Peers: APRE BCDA BIVI CALC CVM GOVX KAPA KPRX LNAI NEUP

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	7.24M
Enterprise Value	6.77M
Income	-11.00M
Sales	0.00M
Book/sh	-0.00
Cash/sh	0.03
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	1
IPO	May 26, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	3.79
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.96
Current Ratio	0.96
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-0.40
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-37.97%
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	41.73%
Insider Trans	0.00%
Inst Own	2.20%
Inst Trans	12.33%
ROA	-788.65%
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-10.09%
SMA50	-22.18%
SMA200	-79.99%
Trades

Shs Outstand	44.88M
Shs Float	39.13M
Short Float	6.14%
Short Ratio	0.08
Short Interest	2.40M
52W High	9.38 -98.85%
52W Low	0.09 13.47%
Volatility	10.22% 18.68%
ATR (14)	0.02
RSI (14)	42.96
Beta	0.73
Rel Volume	0.17
Avg Volume	31.14M
Volume	274,016

Perf Week	-5.52%
Perf Month	8.89%
Perf Quarter	-45.61%
Perf Half Y	-86.06%
Perf YTD	-82.33%
Perf Year	-98.76%
Perf 3Y	-98.97%
Perf 5Y	-98.89%
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	0.11
Price	0.11
Change	-2.80%

Jul-16-26 08:32AM	Why is Cathie Wood's ARK Fund Backing this Israeli Innovator? (NASDAQ: MDWD) (FinanceWire) +29.00%
Jun-30-26 04:30PM	Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline (GlobeNewswire)
Jun-03-26 08:30AM	Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds (GlobeNewswire) -22.21%
May-21-26 08:28PM	Liminatus Pharma Announces Nasdaq Delisting Notification (GlobeNewswire) +30.99% -31.14%
Apr-15-26 10:30AM	BC-Most Active Stocks (Associated Press)
08:08AM	Loading…
Mar-17-26 08:08AM	Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody (GlobeNewswire)
Feb-17-26 08:44AM	Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering (GlobeNewswire) -31.86%
Oct-30-25 10:04AM	Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation (GlobeNewswire)
Aug-22-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +22.66%
Aug-05-25 12:11PM	BNB Falls Below $750 as Crypto Market Sell-Off Erases Corporate-Fueled Optimism (CoinDesk)
Jul-28-25 07:30AM	Liminatus Pharma Inc. to Launch "American BNB Strategy" Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative (GlobeNewswire) -7.23%
Jul-25-25 08:31AM	Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies (GlobeNewswire)
Jul-24-25 08:31AM	Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy (GlobeNewswire) +30.91%
Jul-22-25 01:30PM	Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy (GlobeNewswire)

Liminatus Pharma, Inc. is a pre-clinical stage biopharmaceutical company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in Cerritos, CA.

L.L.M.Mr. Chris Kim J.D.

Chief Financial OfficerMr. Scott Dam

Chief Technology Officer & Member of Scientific Advisory BoardDr. Beom Kyu Choi

Chief Science Officer & Member of Scientific Advisory BoardDr. Byong Chul Yoo Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LIMN

Liminatus Pharma Inc

Upgrade your Finviz experience